21-day dosing regimen for fusion proteins comprising factor IX and human albumin for prophylactic treatment of hemophilia and methods thereof

• 收藏
• 分享

专利权人:

CSL Behring Lengnau AG

发明人:

LI, Yanyan,BENSEN-KENNEDY, Debra,JACOBS, Iris,VOIGT, Christine

申请号：

AU2018294517

公开号：

AU2018294517A1

申请日:

2018.06.29

申请国别(地区):

AU

年份:

2020

代理人:

摘要：

The present invention relates to prophylactic dosing regimens with about 90-110 IU/kg long- acting factor IX (human FIX-human albumin) in dosing intervals of about three weeks (e.g., 21 days).

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/